Akari Therapeutics Board Changes Announced
Ticker: AKTX · Form: 8-K · Filed: Dec 18, 2024 · CIK: 1541157
Sentiment: neutral
Topics: board-change, management
Related Tickers: AKTX
TL;DR
Akari Therapeutics board shake-up: Meanwell in, Warren out.
AI Summary
Akari Therapeutics Plc announced on December 12, 2024, a change in its board of directors. Dr. Clive Meanwell has been appointed as a new director, and Dr. Peter Warren has resigned from his position as a director. The company also disclosed information regarding compensatory arrangements for certain officers.
Why It Matters
Changes in board composition can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Board changes can introduce uncertainty regarding strategic direction and leadership stability.
Key Players & Entities
- Akari Therapeutics Plc (company) — Registrant
- December 12, 2024 (date) — Date of earliest event reported
- Dr. Clive Meanwell (person) — Appointed Director
- Dr. Peter Warren (person) — Resigned Director
FAQ
Who has been appointed as a new director to Akari Therapeutics' board?
Dr. Clive Meanwell has been appointed as a new director.
Who has resigned from Akari Therapeutics' board of directors?
Dr. Peter Warren has resigned from his position as a director.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is December 12, 2024.
What is the primary business of Akari Therapeutics Plc?
Akari Therapeutics Plc is in the Pharmaceutical Preparations industry (SIC code 2834).
What other information is disclosed in this filing besides director changes?
The filing also discloses information regarding compensatory arrangements of certain officers.
Filing Stats: 807 words · 3 min read · ~3 pages · Grade level 11.3 · Accepted 2024-12-18 16:30:06
Key Financial Figures
- $0.0001 — tal Market Ordinary Shares, par value $0.0001 per share* *Trading, but only in conn
Filing Documents
- aktx-20241212.htm (8-K) — 46KB
- 0000950170-24-137922.txt ( ) — 264KB
- aktx-20241212.xsd (EX-101.SCH) — 95KB
- aktx-20241212_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Akari Therapeutics, Plc Date: December 18, 2024 By: /s/ Samir R. Patel, M.D. Samir R. Patel, M.D. President and Chief Executive Officer